> Detailanzeige

Pecoits-Filho, Roberto; McCullough, Keith; Muenz, Daniel; Quinn, Carol Moreno; Budden, Jeff; Golden, John; de Arellano, Antonio Ramirez; Tillmann, Frank-Peter; Duttlinger, Johannes; Calice-Silva, Viviane; Massy, Ziad A; Bieber, Brian; Robinson, Bruce M; Fliser, Danilo; Reichel, Helmut; Lopes, Antonio; Pecoits-Filho, Roberto; Calice da Silva, Viviane; Combe, Christian; Massy, Ziad; Stengel, Benedicte; Speyer, Elodie; Fliser, Danilo; Reichel, Helmut; [...]

Patiromer utilization in patients with advanced chronic kidney disease under nephrology care in Germany

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Patiromer utilization in patients with advanced chronic kidney disease under nephrology care in Germany
  • Beteiligte: Pecoits-Filho, Roberto; McCullough, Keith; Muenz, Daniel; Quinn, Carol Moreno; Budden, Jeff; Golden, John; de Arellano, Antonio Ramirez; Tillmann, Frank-Peter; Duttlinger, Johannes; Calice-Silva, Viviane; Massy, Ziad A; Bieber, Brian; Robinson, Bruce M; Fliser, Danilo; Reichel, Helmut; Lopes, Antonio; Pecoits-Filho, Roberto; Calice da Silva, Viviane; Combe, Christian; Massy, Ziad; Stengel, Benedicte; Speyer, Elodie; Fliser, Danilo; Reichel, Helmut; [...]
  • Erschienen: Oxford University Press (OUP), 2023
  • Erschienen in: Clinical Kidney Journal
  • Sprache: Englisch
  • DOI: 10.1093/ckj/sfac209
  • ISSN: 2048-8505; 2048-8513
  • Schlagwörter: Transplantation ; Nephrology
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>ABSTRACT</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p>Hyperkalemia (HK) is a frequent condition in patients with chronic kidney disease (CKD) that is associated with high morbidity and mortality. Patiromer has recently been introduced as a potassium binder. Data on patiromer use in patients with CKD in the real-world setting in Europe are lacking. We describe time to discontinuation and changes in serum potassium levels among German CKD stage 3–5 patients starting patiromer.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>Duration of patiromer use was estimated by Kaplan–Meier curve, starting at patiromer initiation and censoring for death, dialysis, transplant or loss to follow-up. Serum potassium levels and renin–angiotensin–aldosterone system inhibitor (RAASi) use are described at baseline and during follow-up, restricted to patients remaining on patiromer.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>We identified 140 patiromer users within our analysis sample [81% CKD stage 4/5, 83% receiving RAASi, and median K+ 5.7 (5.4, 6.3) mmol/L]. Thirty percent of patiromer users had prior history of polystyrene sulfonate use. Overall, 95% of patiromer users stayed on treatment past 1 month, with 53% continuing for over a year. Mean serum potassium levels decreased after patiromer initiation and remained stable under treatment during follow-up (up to 180 days). Among these patients, 73%–82% used RAASis during the time periods before and after patiromer initiation, with no obvious trend indicating discontinuation.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion</jats:title> <jats:p>Real-world evidence of patiromer use in Germany shows that, in line with what has been observed in clinical trials, patients on patiromer have a reduction in serum potassium when used long-term. Moreover, most patients on patiromer do not discontinue treatment prior to 1 year after initiation.</jats:p> </jats:sec>
  • Zugangsstatus: Freier Zugang